Peregrine Pharmaceuticals Starts Phase III Lung Cancer Trial

barbara.lempert Peregrine Pharmaceuticals Initiates Sunrise Pivotal Phase III Clinical Trial of Bavituximab in Second-Line Non-Small Cell Lung Cancer Company Launches www.SunriseTrial.com ...

Karolinska’s Axelar comes up short in Phase II with lung cancer drug

Damian Garde Swedish biotech Axelar's lung cancer drug failed to beat out standard docetaxel in a mid-stage trial, but bankroller Karolinska Development isn't giving up, planning ...

OncoNova Discontinues Phase III Pancreatic Cancer Trial

barbara.lempert Onconova Announces Results of Interim Analysis of Metastatic Pancreatic Cancer Study NEWTOWN, Pa., Dec. 17, 2013 (GLOBE NEWSWIRE) — Onconova Therapeutics, Inc. ...

Onconova tanks as its lead candidate flunks PhIII for pancreatic cancer

Damian Garde Onconova Therapeutics' shares took a 16% beating Tuesday night after the company's top prospect, rigosertib, failed a Phase III trial in patients with pancreatic ...

AbbVie’s veliparib wows in a breast cancer study

Damian Garde AbbVie's PARP inhibitor veliparib improved outcomes for women with triple-negative breast cancer in a new investigator-sponsored study, charting a 52% complete response ...

AB Science plummets as EU frowns on cancer drug

Damian Garde France's AB Science watched its shares tank as much as 31% on Friday after a European Medicines Agency panel rejected its gastrointestinal cancer treatment, casting ...

Argos rakes in $17.5M more to wrap up PhIII for cancer drug

Damian Garde Argos Therapeutics is working to get out from under the shadow of Dendreon and its disappointing Provenge, and now the North Carolina company has the cash it needs to get ...

Sanofi, Merrimack cancer drug flops (again) in second round of PhII program

John Carroll Seven months after a mid-stage cancer drug from Sanofi and Merrimack Pharmaceuticals flunked its first mid-stage test, researchers are back with another failure to report. ...

UPDATED: Bristol-Myers adds promising survival update on breakthrough cancer program

John Carroll Bristol-Myers Squibb has added a few more brushstrokes to the very promising picture that's emerging from early-stage studies of nivolumab, a top PD-1 checkpoint receptor ...

Bristol-Myers scores with cancer, diabetes sales hikes

Tracy Staton Bristol-Myers Squibb's third-quarter results amount to a good-news, bad-news report. On the positive side, international sales were up 18%, driving an overall increase ...

AstraZeneca launches PhIII lung cancer study in late-stage rebuilding effort

John Carroll A decade after obtaining the rights to the cancer drug selumetinib from Array Biopharma, the hungry pharma giant AstraZeneca is moving the MEK inhibitor into a late-stage ...

Novartis advances rival CDK 4/6 cancer drug to Pfizer’s palbociclib

John Carroll One of Pfizer's top late-stage prospects is its cancer drug palbociclib, an oral inhibitor of cyclin-dependent kinases (CDK) 4 and 6 that the FDA put in its first group ...
Page 10 of 23« First...89101112...20...Last »
© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS